|
Name |
Cladospolide A
|
Molecular Formula | C12H20O4 | |
IUPAC Name* |
(3E,5R,6S,12R)-5,6-dihydroxy-12-methyl-1-oxacyclododec-3-en-2-one
|
|
SMILES |
C[C@@H]1CCCCC[C@@H]([C@@H](/C=C/C(=O)O1)O)O
|
|
InChI |
InChI=1S/C12H20O4/c1-9-5-3-2-4-6-10(13)11(14)7-8-12(15)16-9/h7-11,13-14H,2-6H2,1H3/b8-7+/t9-,10+,11-/m1/s1
|
|
InChIKey |
PLHJPQNLCWFPFY-OUZGJDHNSA-N
|
|
Synonyms |
Cladospolide A; (-)-Cladospolide A; 77663-54-8; 73G9U1L1XD; (3E,5R,6S,12R)-5,6-dihydroxy-12-methyl-1-oxacyclododec-3-en-2-one; UNII-73G9U1L1XD; 5-EPI-CLADOSPOLIDE C; (3E,5R,6S,12R)-5,6-Dihydroxy-12-methyloxacyclododec-3-en-2-one; CLADOSPOLIDE A, (-)-; Oxacyclododec-3-en-2-one, 5,6-dihydroxy-12-methyl-, (3E,5R,6S,12R)-; Q27896692; (4R,5S,11R,2E)-4,5-DIHYDROXY-2-DODECEN-11-OLIDE; OXACYCLODODEC-3-EN-2-ONE, 5,6-DIHYDROXY-12-METHYL-, (5R-(3E,5R*,6S*,12R*))-
|
|
CAS | 77663-54-8 | |
PubChem CID | 11020642 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 228.28 | ALogp: | 1.4 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 66.8 | Aromatic Rings: | 1 |
Heavy Atoms: | 16 | QED Weighted: | 0.618 |
Caco-2 Permeability: | -4.61 | MDCK Permeability: | 0.00005230 |
Pgp-inhibitor: | 0.964 | Pgp-substrate: | 0.015 |
Human Intestinal Absorption (HIA): | 0.01 | 20% Bioavailability (F20%): | 0.036 |
30% Bioavailability (F30%): | 0.645 |
Blood-Brain-Barrier Penetration (BBB): | 0.98 | Plasma Protein Binding (PPB): | 65.58% |
Volume Distribution (VD): | 0.355 | Fu: | 48.28% |
CYP1A2-inhibitor: | 0.02 | CYP1A2-substrate: | 0.456 |
CYP2C19-inhibitor: | 0.113 | CYP2C19-substrate: | 0.811 |
CYP2C9-inhibitor: | 0.044 | CYP2C9-substrate: | 0.289 |
CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.128 |
CYP3A4-inhibitor: | 0.016 | CYP3A4-substrate: | 0.179 |
Clearance (CL): | 10.903 | Half-life (T1/2): | 0.706 |
hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.258 |
Drug-inuced Liver Injury (DILI): | 0.405 | AMES Toxicity: | 0.947 |
Rat Oral Acute Toxicity: | 0.078 | Maximum Recommended Daily Dose: | 0.471 |
Skin Sensitization: | 0.925 | Carcinogencity: | 0.547 |
Eye Corrosion: | 0.183 | Eye Irritation: | 0.913 |
Respiratory Toxicity: | 0.565 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002200 | 1.000 | D07GRH | 0.323 | ||||
ENC004377 | 0.679 | D04URO | 0.273 | ||||
ENC003404 | 0.679 | D03DVJ | 0.250 | ||||
ENC004602 | 0.563 | D08MRN | 0.238 | ||||
ENC004599 | 0.563 | D0P6VV | 0.234 | ||||
ENC003186 | 0.521 | D0N4PZ | 0.230 | ||||
ENC006036 | 0.521 | D0Z1FX | 0.226 | ||||
ENC001414 | 0.516 | D0D1SG | 0.223 | ||||
ENC003460 | 0.515 | D07WFK | 0.221 | ||||
ENC003784 | 0.515 | D0L9ZR | 0.220 |